Le Lézard
Classified in: Health
Subject: PER

Therigy Announces Strategic Organizational Changes for Greater Scalability and Growth in 2018


MAITLAND, Fla., Dec. 13, 2017 /PRNewswire/ -- Therigy® announced today two key leadership changes within the organization.

Lily P. Duong, PharmD, Therigy's Vice President of Clinical Programs, has been promoted to Chief Clinical Officer. Dr. Duong has been responsible for the development of Therigy's drug therapy management programs and clinical reporting. Lily joined Therigy in 2013 and brought with her many years of clinical operations management and clinical program development.

Russel Allinson, RPh, MS, Therigy's CEO, said of Dr. Duong, "It has been an honor to watch Lily grow in her current role over the past several years. Her deep knowledge of the specialty pharmacy industry is expansive and has been invaluable in the development of our clinical programs and collaborating on technology advances. In promoting her to Chief Clinical Officer, I know she will continue to lead by example and drive our strategic business efforts forward. Our DNA is about marrying therapy management solutions with technology and this role is a perfect fit for her."

Lily received both her B.S and Doctor of Pharmacy degree from Temple University School of Pharmacy. She also holds a B.S. in chemical engineering from Drexel University.

In addition to Ms. Duong's promotion, Jon Hamrick, MBA, Therigy's Chief Strategy Officer has been named Chief Operating Officer effective immediately. Mr. Hamrick joined Therigy in 2011 as a principal partner. His expansive 25-year career in the pharma and specialty pharmacy industry is an invaluable asset. As the Chief Strategy Officer, Jon has successfully spearheaded the business development and collaboration with specialty pharmacy customers, Pharma and other healthcare industry partners to develop quality and outcomes programs. Over the last several months, Jon has been steadily taking on additional projects on the operations side of the business, thereby making his transition to COO a natural one.

Of the transition, Joe Morse, Therigy's President, said, "Jon is a natural choice for this role. His leadership and organizational development skills will go a long way toward bringing Therigy forward into the next phase of our growth within the marketplace." Mr. Hamrick will maintain responsibility for Therigy's Pharma Services Division while transitioning to his new role.

Jon earned his Bachelor of Arts degree in History from the University of Central Florida and his MBA from the University of Florida Warrington College of Business.

Therigy congratulates both Dr. Duong and Mr. Hamrick as they embark on their new roles. Their constant commitment to achieving company goals and leading their teams will help position Therigy for continued growth in the new year ahead.

ABOUT THERIGY

Therigy® is a patient-focused specialty therapy management company. As an industry pioneer, Therigy continues to lead the specialty pharmacy market as the top choice in technology and consulting solutions ? with the best possible outcomes for patients in mind. Therigy equips pharmacy stakeholders with the tools to standardize and scale patient management programs ? with a depth and consistency of clinical care never before possible ? helping them to deliver value-based outcomes, gain insights into evolving patient needs, and predict therapy trends. Learn more about Therigy at www.therigy.com.

Contact:
Katharine Powell
Email: [email protected]

SOURCE Therigy LLC


These press releases may also interest you

at 11:15
Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market....

at 11:15
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first Biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of NIOPEG® (a...

at 11:00
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam's appointment follows an extensive...

at 11:00
MasterControl, a leading provider of quality management and manufacturing execution software for life sciences, announced it has been recognized by the Imapac 2024 Asia-Pacific Biopharma Excellence Awards in the "Best Bioprocessing Supplier:...

at 10:36
Senstar Technologies Corporation , a leading international provider of comprehensive physical, video and access control security products and solutions, announced today that its Annual Report on Form 20-F for the year ended December 31, 2023 has been...

at 10:33
The report titled "Peptide Therapeutics Market by Technology (Hybrid Phase, Liquid Phase, Solid Phase), Drug Class (Adrenocorticotropic Hormone, Calcitonin, Insulin), Route of Administration, Application, End User, Manufacturing Type - Global...



News published on and distributed by: